Déjà vu: GSK recycles its problematic adjuvant into COVID-19 vaccines

Share it with your friends Like

Thanks! Share it with your friends!

Close

Among the 100 or so global players now working on experimental Covid-19 vaccines, most of the entities touted as frontrunners are obscure biotechnology and nanotechnology firms. Despite their focus on razzle-dazzle “next-generation” technologies that private foundations, the U.S. government and the military apparently find alluring, few of these companies have any prior experience successfully bringing vaccines to market. In contrast, some of the biggest and most experienced vaccine manufacturers in the U.S. and globally, including Merck, Sanofi and GlaxoSmithKline (GSK), seemed, until recently, to be missing in action — “conspicuously absent” from the frontrunner lists. In May, a Merck executive …read more

Source: Sott health news feed

    

  • Rating:
  • Views:208 views
  • Categories: Health